Skip to main content Deutsch


Johannes Gojo
Johannes Gojo, MD, PhD, BScHead of Pediatric Precision Oncology CNS and ITCC-Lab/Clinical Trials Unit

Department of Pediatrics and Adolescent Medicine (Division of Neonatology, Intensive Care Medicine and Neuropediatrics)
Position: Assistant Professor

ORCID: 0000-0002-8113-3416


Brain tumor biomarkers; Neurooncology; Rare Diseases

Research group(s)

  • Pediatric Neuro-Oncology
    Research Area: - Precision oncology for pediatric CNS tumors - Development of innovative tumor models for pediatric CNS tumors - Identification of novel targets and therapies for pediatric CNS tumors - Discovery and translational application of biomarkers with focus on liquid biopsy

Research interests

My research is focused on delivering precision medicine approaches to children suffering from tumors of the central nervous system (CNS). A particular focus is the development of innovative tumor models for these rare diseases in order to allow detailed preclinical research. Therefore, my research interests range from deciphering the molecular mechanisms underlying the malignant phenotype of pediatric high-risk CNS tumors to develpment of novel biomarkers for disease montoring such as liquid biopsies.

Current ongoing projects are focused on various high-risk brain tumors including ependymoma, HGNET-BCOR, high-grade glioma and ETMR.

Techniques, methods & infrastructure

- precision oncology

- in vitro patient-derived cell models

- liquid biopsy (cerebrospinal fluid, blood)

Selected publications

  1. Mayr, L. et al., 2020. Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 10(4), p.290. Available at:
  2. Gojo, J. et al., 2020. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 38(1), pp.44,
  3. Guntner, A.S. et al., 2020. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathologica Communications, 8(1). Available at:
  4. Gojo, J. et al., 2020. Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. Frontiers in Oncology, 9. Available at:
  5. Gojo, J. et al., 2017. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 19(9), pp.1183,